Tandem Diabetes Care/$TNDM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.
- Ticker
- $TNDM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- San Diego, United States
- Website
- www.tandemdiabetes.com
TNDM Metrics
BasicAdvanced
$1.3B
-
-$0.93
1.54
-
Price and volume
Market cap
$1.3B
Beta
1.54
52-week high
$29.65
52-week low
$12.26
Average daily volume
2.3M
Financial strength
Current ratio
3.18
Quick ratio
2.443
Long term debt to equity
5.514
Total debt to equity
5.67
Interest coverage (TTM)
-4.89%
Profitability
EBITDA (TTM)
-25.033
Gross margin (TTM)
56.01%
Net profit margin (TTM)
-6.08%
Operating margin (TTM)
-4.13%
Effective tax rate (TTM)
-3.80%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-2.65%
Return on equity (TTM)
-48.03%
Valuation
Price to revenue (TTM)
1.253
Price to book
10.19
Price to tangible book (TTM)
10.19
Price to free cash flow (TTM)
-21.132
Free cash flow yield (TTM)
-4.73%
Free cash flow per share (TTM)
-0.904
Growth
Revenue change (TTM)
3.96%
Earnings per share change (TTM)
-70.10%
3-year revenue growth (CAGR)
9.63%
10-year revenue growth (CAGR)
28.05%
3-year earnings per share growth (CAGR)
-35.65%
10-year earnings per share growth (CAGR)
-27.56%
What the Analysts think about TNDM
Analyst ratings (Buy, Hold, Sell) for Tandem Diabetes Care stock.
Analyst projections of the future price of Tandem Diabetes Care stock.
Bulls say / Bears say
Tandem’s operating trend is improving: second-quarter sales rose 6% year on year to $254.6 million, gross margin reached 57% and operating margin improved by 8 percentage points. It reaffirmed full-year sales guidance of $1.065 billion to $1.085 billion. (Tandem Diabetes Care)
Mobi accounted for more than half of Tandem’s new pump starts in the second quarter. A pending tubeless option could widen its appeal by letting users switch between tubed and tubeless wear on the same pump. (The Motley Fool, MedTech Dive)
Tandem Mobi is now available in 12 international markets, extending the company’s reach beyond the US and creating room to grow its customer base and recurring supply sales. (Business Wire)
The company still reported a $21.2 million net loss in the second quarter, despite higher sales and margins. Its reaffirmed 2026 outlook implies adjusted EBITDA margins of only 5% to 6%, so a durable move to profitability remains unproven. (Tandem Diabetes Care, Simply Wall St)
A shortage at a third-party infusion-set supplier held back supply sales and delayed distributor orders in the second quarter. Tandem expected some effects to continue over the following quarters, leaving revenue exposed to a supplier it does not control. (The Motley Fool)
Tubeless Mobi still requires FDA clearance, and other companies are developing competing patch pumps. Regulatory or launch delays, or weaker uptake against those rivals, could limit the growth Tandem expects from entering this market. (MedTech Dive, DiabeTech)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
TNDM Financial Performance
Revenues and expenses
TNDM Earnings Performance
Company profitability
Upcoming events
No upcoming events
TNDM News
AllArticlesVideos
Funds containing TNDM
AllUSDEURGBP
Fund name | Fund size | $TNDM weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.13% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.13% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.13% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.